Medicure Inc. reported higher revenue in the second quarter of 2026, even as its net loss widened compared with the prior-year period, according to a transcript of the company’s earnings call.
The Canadian biopharmaceutical company disclosed that revenue for the three months ended December 31, 2025, increased year-over-year, though it did not provide specific figures in the transcript. The company’s net loss expanded during the same period, reflecting higher operating costs and investment in research and development.
Medicure attributed the revenue growth to continued demand for its cardiovascular and thrombosis-focused therapies, which remain core to its product portfolio. Management highlighted ongoing commercialization efforts and market penetration as key drivers behind the top-line improvement.
Despite the revenue increase, the widening net loss underscores the company’s elevated spending on R&D and commercial infrastructure. Medicure emphasized its commitment to advancing late-stage pipeline candidates, which are expected to contribute to future profitability once approved and launched.
The company’s leadership noted that while near-term financial performance remains pressured by investment priorities, the strategic focus on high-value therapeutic areas positions Medicure for long-term growth. No further financial details were disclosed in the transcript.
